Clinical Trials Logo

Impaired Glucose Tolerance clinical trials

View clinical trials related to Impaired Glucose Tolerance.

Filter by:

NCT ID: NCT04088461 Completed - Insulin Resistance Clinical Trials

Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine

RESCATHEME
Start date: September 2016
Phase: Phase 4
Study type: Interventional

The goal of this protocol is to evaluate the effect of addhing linagliptin to patients with prediabetes who do not reverse to normoglycemia after 12 months of treatment with metformin alone. The duration of the study will be 6 months, and it is primarily a efficacy study. Main outcomes will be glucose levels during OGTT, insulin secretion and pancreatic beta cell function measured by the disposition index derived from the OGTT.

NCT ID: NCT04018105 Not yet recruiting - Type2 Diabetes Clinical Trials

Influence of Preprandial Metformin Administration on Carbohydrate Absorption

METTIME
Start date: December 2022
Phase: N/A
Study type: Interventional

Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption. It is usually recommended to take metformin during the meal to decrease gastrointestinal side effects. However, if metformin decreases carbohydrate absorption, this might not be the most efficient intake. To study the influence of preprandial metformin administration on carbohydrate absorption, it will repeat 3 oral glucose tolerance test on obese dysglycemic patients, without metformin or with metformin administer 30 or 60 minutes before. We will also evaluate how it impacts gastrointestinal tolerance.

NCT ID: NCT03945435 Completed - Clinical trials for Impaired Glucose Tolerance

Mechanisms of Exercise Resistance in Metabolic Disease

Start date: July 1, 2018
Phase:
Study type: Observational

This project will determine exercise capacity and molecular markers of the response to acute exercise in human subjects with impaired or normal glucose tolerance.

NCT ID: NCT03938389 Active, not recruiting - Obesity Clinical Trials

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

Start date: February 25, 2020
Phase: Phase 4
Study type: Interventional

The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with impaired glucose tolerance. The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater improvement in insulin release from the pancreas and improved blood sugar compared to RAAS inhibition alone among AAs with impaired glucose tolerance.

NCT ID: NCT03764423 Completed - Clinical trials for Impaired Glucose Tolerance

Health Effects of Salmon Fishmeal in Humans

FishMeal
Start date: September 14, 2018
Phase: N/A
Study type: Interventional

Diabetes contributes significantly to the burden of disease in Norway and cardiovascular disease is the main cause of mortality. Both lean and fatty fish are shown to have beneficial health effects. In addition to omega-3 fatty acids, fish contain potential health-promoting components such as taurine, vitamin D, vitamin B12, iodine, selenium and more unspecified components such as bioactive peptides. With the expected growth in the aquaculture sector, more protein-rich by-products will become available. The overall aim of this project is to investigate the health beneficial effects of fish protein in the form of salmon fishmeal in a human intervention study with regard to metabolic risk markers. We will include subjects with impaired glucose tolerance to a randomized controlled parallel study. The subjects will receive capsules with fishmeal or placebo.

NCT ID: NCT03725033 Completed - Clinical trials for Impaired Glucose Tolerance

Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

Start date: October 10, 2018
Phase: Phase 3
Study type: Interventional

Purpose of the study: - to assess the efficacy of Subetta in the treatment of impaired glucose tolerance - to assess the safety of Subetta in the treatment of impaired glucose tolerance.

NCT ID: NCT03650023 Completed - Clinical trials for Impaired Glucose Tolerance

A Crossover Trial of Chitosan Oligosaccharide on Post Prandial Glucose Control in Subjects With Normal, IFG and IGT

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

It is well known that Chitosan oligosaccharide is low molecular weight and water soluble and chitosan oligosaccharide has been shown to reduce blood cholesterol and blood pressure, increase immunity, and enhance antitumor properties. the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with normal blood glucose, impaired fasting glucose and impaired glucose tolerance.

NCT ID: NCT03419702 Completed - Clinical trials for Overweight and Obesity

Almonds and Health Effects on Metabolism, Vascular Function and Cognition

Start date: January 10, 2018
Phase: N/A
Study type: Interventional

The primary objective of the proposed study is to examine and understand the impact of long-term almond consumption on chronic glucose metabolism in subjects with impaired glucose tolerance and/or impaired fasting glucose.

NCT ID: NCT03383068 Not yet recruiting - Clinical trials for Impaired Glucose Tolerance

Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

PCOS
Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

To investigate whether intensive metabolic intervention of PCOS women before pregnancy can improve pregnancy outcome.Besides, the investigators aim to investigate the best therapy strategy of metabolic intervention before pregnancy.The investigators plan to recruit PCOS women at childbearing age. By using acarbose, GLP-1 analogue, berberin et al. the investigators will intervent the participants' metabolic statues for 3 months before pregnancy and to compare outcome in each group.

NCT ID: NCT03343262 Not yet recruiting - Clinical trials for Impaired Glucose Tolerance

Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Impaired Glucose Tolerance (IGT) is an abnormal metabolic state following glucose metabolic steady state but prior to diabetes. IGT is an important stage during the progression of diabetes, with an underlying mechanism of insulin resistance and pancreatic β cell dysfunction. IGT is one of the diseases that shows significant beneficial response to acupuncture treatment. Original findings from the investigators'laboratory show that transcutaneous auricular vagus nerve stimulation (taVNS) which is innervated by vagus nerve, would enhance the activity of pancreatic β cells, promote the secretion of insulin, upregulate the expression of insulin receptors in central as well as peripheral tissues, thus to improve glycometabolism. In this study, the investigators would further illuminate the mechanism of taVNS at "yidan-pi" auricular acupoints on the regulation of glucose metabolism, its improvement of the IGT state in rat model, as well as its regulation effect on insulin receptor expression and insulin resistance, and systematically illustrate the clinical effective of this treatment on IGT, with emphasize on its influence on the concentrations of glucose and HbA1c, and thus provide an effective proposal for clinical acupuncture.